source
- Agios halts development of tebapivat for low-risk MDS after disappointing Phase 2b dataAgios Pharmaceuticals announced it will discontinue development of its pyruvate kinase activator tebapivat for patients with low-risk myelodysplastic syndromes (MDS). The decision follows the relea…
- US says Ebola patients will be evacuated to Europe, not treated in America, as outbreak growsThe World Health Organization is reviewing which vaccines could help curb the expanding Ebola outbreak in Africa. The U.S. government announced it will no longer bring Americans infected with Ebol…